Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02434393 · ClinicalTrials.gov registry record

Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project

A clinical trial of Major Depression and Late Life Depression (LLD), sponsored by University of Southern California.

Recruiting
Registry status
120
Enrollment target
2
Study locations

NCT02434393: Recruiting study of Major Depression and Late Life Depression (LLD), sponsored by University of Southern California.

NCT02434393 is a study of Major Depression and Late Life Depression (LLD) that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 120 participants, below the 323-participant average among 28 other Major Depression trials with a reported enrollment target (63% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02434393, a study of Major Depression and Late Life Depression (LLD), is actively recruiting participants, sponsored by University of Southern California.

RECRUITING
Registry status
120 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD). This is a non-randomized, observational, non-treatment study that originally launched in 2015, enrolling 133 participants. From the originally enrolled participants, the continuation of the ADNI-D study will enroll 120 participants which will include following participants from the original (parent) protocol and enrollment of new participants for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison. Depression history, symptom severity and health information will be collected at the initial visit to determine eligibility. An magnetic resonance imaging (MRI) scan, as well as amyloid (florbetapir) and tau (flortaucipr) positron emission tomography (PET) imaging will be conducted at San Francisco VA. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.

Primary Outcome

The Digit Symbol subtest is a measure of attention, working memory, and information processing speed. Participants are presented with a stimulus sheet, and asked to write in the correct symbol that corresponds with a number keyed at the top of the page. A scaled score is calculated based on the number of total correct responses.

Study Locations (2)

California

  • University of California, San Francisco - San Francisco

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2015-03-04
Est. Completion 2027-05
University of Southern California

617 total trials

What NCT02434393 shows while recruiting

NCT02434393 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 323-participant average among 28 other Major Depression trials with a reported enrollment target (63% lower).

The record links to 2 conditions, with Major Depression appearing as the primary indexed condition, and to 0 interventions.

NCT02434393 reports a single indexed study location in California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02434393 about?

NCT02434393 is a clinical study titled "Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project". The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD). This is a non-randomized, observational, non-treatment study that originally launched in 2015, enrolling 133 participants. From ...

What is the current status of trial NCT02434393?

This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2015-03-04. Estimated completion is 2027-05.

What conditions does trial NCT02434393 study?

This clinical trial studies the following conditions: Major Depression, Late Life Depression (LLD).

Who is sponsoring clinical trial NCT02434393?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02434393 being conducted?

This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02434393's enrollment target sits among peer trials

120 14th of 28 higher than 15 of 28 other Major Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02434393, the US trial registry maintained by the National Library of Medicine. NCT02434393 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.